2006-000501-37: Monozentrische, offene Therapiestudie zur Behandlung von Psoriasis-Patienten ab vollendetem 18. Lebensjahr mit Fumaderm® in Kombination mit einer UVB-Therapie (311 nm) im intraindividuellen Halbseitenvergleich |
|
|
| Ongoing | 4 | 12 | Europe | Fumaderm initial, Fumaderm, Fumaderm initial, Fumaderm, Fumaderm initial, Fumaderm | Technical University Carl-Gustav-Carus | Psoriasis vulgaris | | | | |
2010-018517-29: Topoproteome-Analysis of Psoriasis under Fumarate-Treatment. |
|
|
| Ongoing | 4 | 15 | Europe | Fumaderm initial (Dimethylfumarate 30 mg, Ethylhydrogenfumarate Ca-salt 67 mg, Ethylhydrogenfumarate Mg-salt 5 mg, Ethylhydrogenfumarate Zinc-salt 3 mg), Fumaderm (Dimethylfumarate 120 mg, Ethylhydrogenfumarate Ca-salt 87 mg, Ethylhydrogenfumarate Mg-salt 5 mg, Ethylhydrogenfumarate Zinc-salt 3 mg), Fumaderm initial (Dimethylfumarate 30 mg, Ethylhydrogenfumarate Ca-salt 67 mg, Ethylhydrogenfumarate Mg-salt 5 mg, Ethylhydrogenfumarate Zinc-salt 3 mg), Fumaderm (Dimethylfumarate 120 mg, Ethylhydrogenfumarate Ca-salt 87 mg, Ethylhydrogenfumarate Mg-salt 5 mg, Ethylhydrogenfumarate Zinc-salt 3 mg) | Medical Faculty, Otto-von-Guericke-University Magdeburg | Fumaderm initial / Fumaderm will be used in this CT completely \"in-label\", i.e. for the treatment of adult patients of both genders with moderate to severe plaque psoriasis in so far as a solely topical treatment is not sufficient. The treatment will last for a defined study period of 16 weeks (and facultatively over an additional 4 weeks during the follow-up). | | | | |
2012-000035-82: A clinical study to evaluate the efficacy and safety of Fumaderm® in young patients aged 10 to 17 years with moderate to severe psoriasis vulgaris (KIFUderm study). |
|
|
| Ongoing | 3 | 133 | Europe | Fumaderm® Initial, Fumaderm®, Fumaderm® Initial, Fumaderm® | Biogen GmbH, Biogen GmbH | Psoriasis vulgaris | | | | |
2011-000659-18: Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients |
|
|
| Ongoing | 2 | 40 | Europe | Fumaderm, Fumaderm initial, Tablet, Fumaderm, Fumaderm initial | University Hospital Tübingen, Biogen Idec | Alopecia areata, Alopecia arata, Body processes [G] - Immune system processes [G12] | | | | |
